Increased PrLZ-mediated androgen receptor transactivation promotes prostate cancer growth at castration-resistant stage.
about
Androgen receptor enhances kidney stone-CaOx crystal formation via modulation of oxalate biosynthesis & oxidative stress.PC-1/PrLZ confers resistance to rapamycin in prostate cancer cells through increased 4E-BP1 stabilityAndrogen receptor (AR) signaling promotes RCC progression via increased endothelial cell proliferation and recruitment by modulating AKT → NF-κB → CXCL5 signaling.Suppression of PC-1/PrLZ sensitizes prostate cancer cells to ionizing radiation by attenuating DNA damage repair and inducing autophagic cell death.PC-1 works in conjunction with E3 ligase CHIP to regulate androgen receptor stability and activity.The Multifaceted Roles of STAT3 Signaling in the Progression of Prostate Cancer.Tumor protein D52 (TPD52) and cancer-oncogene understudy or understudied oncogene?Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9(®) to Suppress Enzalutamide-resistant Prostate Cancer Progression.Role of STAT3 pathway in genitourinary tumors.Isoform 1 of TPD52 (PC-1) promotes neuroendocrine transdifferentiation in prostate cancer cells.G6PD downregulation triggered growth inhibition and induced apoptosis by regulating STAT3 signaling pathway in esophageal squamous cell carcinoma.Tumour-suppressive microRNA-224 inhibits cancer cell migration and invasion via targeting oncogenic TPD52 in prostate cancer.Regulation of TPD52 by antitumor microRNA-218 suppresses cancer cell migration and invasion in lung squamous cell carcinoma.Loss of miR-449a-caused PrLZ overexpression promotes prostate cancer metastasisPrLZ increases prostate cancer docetaxel resistance by inhibiting LKB1/AMPK-mediated autophagy.Tumor protein D52 (isoform 3) contributes to prostate cancer cell growth via targeting nuclear factor-κB transactivation in LNCaP cells.Androgen-dependent alternative mRNA isoform expression in prostate cancer cells
P2860
Q33977438-D6800856-E939-4412-A5E5-A46CDDC9608BQ36299687-D1289CAD-ABC8-4051-A8DF-304E02A34B2BQ37416749-4D839F9E-3E67-4AD3-B763-D7DB92F41D6DQ37641774-101FDC41-25B9-4333-8F74-DA402521C736Q37697163-D5ACAE22-64FB-4D4F-84E6-7291442260ACQ38203779-AC395D6C-A332-4340-9B72-2E4922075765Q38209599-36294ED8-8933-44CA-B7BE-5997C986FFDBQ38681329-829E5DAE-48AA-46FD-B5DD-5CF83334ACCAQ38776978-0B33039F-4201-4408-8AAE-A7516E0D7015Q38796619-AB6051DA-A159-4BBE-967B-290895433E91Q38845707-19A501C8-5AFA-4E1E-9463-5529210A3BA6Q39001066-735C53CE-448A-46F9-A3E1-81F670283080Q39384713-8A83E1A1-03B9-471E-82C2-A49034352F50Q40979880-10C9523E-1301-4AB6-9AF0-04EA2EB4A1D5Q47139658-22EB82E6-E3E2-478C-A7DF-96FDF78204F0Q51022990-F21215AE-88B0-41FD-8130-80BE71C8F110Q57135534-99454768-01D1-4E90-B70F-FD62F390B397
P2860
Increased PrLZ-mediated androgen receptor transactivation promotes prostate cancer growth at castration-resistant stage.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Increased PrLZ-mediated androg ...... at castration-resistant stage.
@ast
Increased PrLZ-mediated androg ...... at castration-resistant stage.
@en
type
label
Increased PrLZ-mediated androg ...... at castration-resistant stage.
@ast
Increased PrLZ-mediated androg ...... at castration-resistant stage.
@en
prefLabel
Increased PrLZ-mediated androg ...... at castration-resistant stage.
@ast
Increased PrLZ-mediated androg ...... at castration-resistant stage.
@en
P2093
P2860
P356
P1433
P1476
Increased PrLZ-mediated androg ...... at castration-resistant stage.
@en
P2093
Chawnshang Chang
Dong Zhang
Hongjun Xie
Leiya Fang
Liang Liang
Luke S Chang
Shuyuan Yeh
P2860
P304
P356
10.1093/CARCIN/BGS337
P407
P577
2012-10-26T00:00:00Z